NexGenix is a privately-held drug discovery and development company focused on the "next generation" of targeted therapies for cancer and diseases of the nervous system such as glioblastoma, neurodegenerative diseases, neurofibromatosis, and autism-spectrum disorders. The Company has acquired, through in-licensing and research collaboration, a robust structural chemistry platform in resorcylic macrolides, highly potent inhibitors of the chaperone, heat shock protein 90 (Hsp90). The concept that numerous diseases, including cancer, neurofibromatosis, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and Parkinson's disease involve misregulation of protein homeostasis presents a unique opportunity for drug development for these varied disorders. NexGenix's novel Hsp90 inhibitors, based on the highly potent compound radicicol, exhibit the potential to be best in class drugs.
NexGenix also has a research stage program evaluating the utility of novel inhibitors of the p21-activated kinases (Pak) for neurofibromatosis and autism-spectrum disorders including Fragile X Syndrome. In addition, the Company has a clinical stage program involving the development of a non-surgical treatment for dermal neurofibromas, the commonest lesion in the genetic disorder neurofibromatosis type 1 (NF1), based on a vascular disruption mechanism.